Does using topical latanoprost affect subfoveal choroidal thickness?

Duru, Zeynep; Özsaygılı, Cemal; Ulusoy, Döndü Melek; Demirtaş, Atılım Armağan; Çiçek, Ayşe; Duru, Necati

doi:10.1080/15569527.2019.1632884

Cited by 3 publications

(8 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Topical prostaglandin analogue bimatoprost is associated with an increase in CT 11 . Another topical prostaglandin analogue, latanoprost (isopropyl ester), is associated with no significant change in SFCT in 2 studies 10,51 and a significant increase in SFCT in a third study 50 . Of note, the duration of therapy was shorter in the 2 studies, finding no difference in CT (45 min 10 and 1 mo), 51 compared to the study finding a significant increase (3 mo 50 ).…”

Section: Resultsmentioning

confidence: 93%

“…Another topical prostaglandin analogue, latanoprost (isopropyl ester), is associated with no significant change in SFCT in 2 studies 10,51 and a significant increase in SFCT in a third study 50 . Of note, the duration of therapy was shorter in the 2 studies, finding no difference in CT (45 min 10 and 1 mo), 51 compared to the study finding a significant increase (3 mo 50 ). Researchers have hypothesized that prostaglandins may both decrease choroidal extracellular matrix and increase choroidal blood flow, leading to a finding of no net change in CT initially 51 .…”

Section: Resultsmentioning

confidence: 94%

“…Researchers have hypothesized that prostaglandins may both decrease choroidal extracellular matrix and increase choroidal blood flow, leading to a finding of no net change in CT initially 51 . It has been suggested that after 3 months of therapy, the predominant effect of latanoprost is increased volume of aqueous humour flow to the choroid, leading to increased CT 50 . Instillation of 1% pilocarpine in healthy patients was shown to decrease SFCT by 2–5% and this effect was more pronounced in eyes with a short axial lengths and thicker choroids 26 …”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

The effect of systemic and topical ophthalmic medications on choroidal thickness: A review

Yeung

Park

et al. 2022

Brit J Clinical Pharma

View full text Add to dashboard Cite

The choroid plays an important role in various ocular pathologies and retinal blood supply. There is a knowledge gap on how the choroid is affected by systemic and topical medications. Systemic medications that affect microvasculature elsewhere in the body can also affect the microvasculature of the choroid. This review summarizes current knowledge on associations between systemic and topical medications and changes in choroidal thickness (CT). This review included 71 studies on mydriatics/cycloplegics, intraocular pressure (IOP)‐lowering therapies, antihypertensives, adrenergic antagonists, statins, corticosteroids, hydroxychloroquine, isotretinoin, hormonal contraceptives, phosphodiesterase inhibitors, antipsychotics, antineoplastic agents, ethanol, caffeine and nicotine. IOP‐lowering therapies, atropine eye drops, and systemic administration of β blockers and ethanol are associated with a significant increase in CT. Cyclopentolate and phenylephrine are associated with a CT reduction. Systemic medications that decrease CT include caffeine and nicotine. Tropicamide, angiotensin‐converting enzyme inhibitors, angiotensin receptor blockers, statins, corticosteroids, hydroxychloroquine and hormonal contraceptives have mixed findings. CT increase associated with IOP‐lowering therapies is possibly achieved by enhancing aqueous humour flow to the choroid thus elevating choroidal blood flow and thickness. CT changes appear to be independent from systemic blood pressure changes, suggesting that a significant association with an antihypertensive could be due to an idiosyncratic drug property. Statins and candesartan decrease macrophage accumulation and intercellular adhesion molecule 1 expression in the choroid. The choroid and its response to various disease processes and systemic medication can be further investigated to improve patient care, particularly in patients with choroid and retina pathologies.

show abstract

Section: Resultsmentioning

confidence: 93%

Section: Resultsmentioning

confidence: 94%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The effect of systemic and topical ophthalmic medications on choroidal thickness: A review

Yeung

Park

et al. 2022

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…Different results have been found regarding the effect of latanoprost on central choroidal thickness (CT). Sahinoglu-Keskek and Canan10 reported that there was no change in the central CT; however, the central CT was found to have increased after the use of latanoprost in a study by Duru et al11…”

mentioning

confidence: 95%

“…9 Different results have been found regarding the effect of latanoprost on central choroidal thickness (CT). Sahinoglu-Keskek and Canan 10 reported that there was no change in the central CT; however, the central CT was found to have increased after the use of latanoprost in a study by Duru et al 11 Agrawal et al 12 described a new marker called the choroidal vascularity index (CVI). Using an image binarization technique, the choroid may be separated into a stromal area (SA) and a luminal area (LA), allowing the vascular state to be assessed particularly.…”

mentioning

confidence: 99%

The Effect of Latanoprost on Choroidal Vascularity Index in Glaucoma and Ocular Hypertension

Çakır

Pehlivanoğlu

Yalçınkaya

et al. 2022

Journal of Glaucoma

View full text Add to dashboard Cite

The choroidal vascularity index (CVI) is a new marker for the choroid. The decrease in CVI following latanoprost use can provide a better understanding of the pathogenesis of the posterior segment side effects of latanoprost such as cystoid macular edema and central serous choroidopathy.Purpose: The purpose of this paper is to evaluate the changes in the CVI, total choroidal area (TCA), stromal area (SA), luminal area (LA), and choroidal thickness (CT) following latanoprost therapy in patients with primary open angle glaucoma and ocular hypertension.Materials and Methods: Patients with newly diagnosed primary open angle glaucoma or ocular hypertension who had never received antiglaucoma therapy were included. Each patient received latanoprost 0.005% once daily. Enhanced depth imaging mode of spectral-domain optical coherence tomography scans was taken before the start of latanoprost therapy and in the first and third months. Subfoveal CT, CVI, TCA, LA, and SA for the submacular area, and 4 quadrants of the peripapillary area were calculated from the scans.Results: A total of 36 eyes of 18 patients were analyzed. Subfoveal CT increased significantly (P = 0.007). Mean TCA (P = 0.008) and SA (P < 0.001) in the first and third months were higher than baseline in the submacular regions. Mean CVI was lower in the first and third months (P < 0.001). There was an increase in the mean TCA and SA in the peripapillary temporal (P = 0.001 and 0.028) and inferior (P = 0.002 and <0.001) quadrants and a decrease in mean CVI in the temporal (P = 0.027) and inferior (P = 0.003) peripapillary quadrants. A negative correlation was found between the rate of decrease in intraocular pressure and the macular region CVI.Conclusions: Following latanoprost use for several months, the CVI was significantly decreased in newly treated patients with glaucoma or ocular hypertension, among other changes to the choroid. These findings may contribute to a better understanding of the effects of prostaglandins on the posterior segment of the eye.

show abstract

Treatment of glaucoma and ocular hypertension using rho kinase inhibitors: patent evaluation of US2018244666 and US2018256595

Bonardi

Supuran

2019

Expert Opinion on Therapeutic Patents

View full text Add to dashboard Cite

Does using topical latanoprost affect subfoveal choroidal thickness?

Cited by 3 publications

References 29 publications

The effect of systemic and topical ophthalmic medications on choroidal thickness: A review

The effect of systemic and topical ophthalmic medications on choroidal thickness: A review

The Effect of Latanoprost on Choroidal Vascularity Index in Glaucoma and Ocular Hypertension

Treatment of glaucoma and ocular hypertension using rho kinase inhibitors: patent evaluation of US2018244666 and US2018256595

Contact Info

Product

Resources

About